On Wednesday, the Food and Drug Administration issued a warning, calling compounded GLP-1 medications "risky for patients." "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss," the FDA said
Planning Ahead for Long Trips For longer trips lasting several weeks or months, additional planning may help avoid disruptions
Ro is not the right choice for those who cant or dont want to use injections
Obesity 26(12):18341840 Bessesen DH, Van Gaal LF (2018) Progress and challenges in anti-obesity pharmacotherapy
The peptide is typically supplied as a lyophilized powder (e.g., 5 mg, 10 mg, 20 mg per vial) that must be reconstituted with bacteriostatic water before injection
Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly